Navigation Links
Iomai Announces Data from Phase 2 Field Study of Travelers' Diarrhea Vaccine Accepted for Presentation at ICAAC
Date:8/23/2007

GAITHERSBURG, Md., Aug. 23 /PRNewswire-FirstCall/ -- Iomai Corporation (Nasdaq: IOMI) today announced that the abstract detailing efficacy and safety results from its double-blind Phase 2 field study of a patch-based vaccine for travelers' diarrhea has been accepted as a "late breaker" presentation at Interscience Conference on Antimicrobials and Chemotherapy (ICAAC), to be held in Chicago Sept. 17 to 20.

The abstract, "Transcutaneous Immunization with the Heat Labile Toxin (LT) of Enterotoxigenic Escherichia coli (ETEC) Protects in a Phase 2 Field Trial in Travelers to Guatemala and Mexico," will be presented by Gregory Glenn, M.D., Iomai's chief scientific officer, on Tuesday, Sept. 18, during the session on "Vaccines and Pediatric Infections." The session will be held from 1:30 to 4 p.m.

About Travelers' Diarrhea

This year, approximately 55 million international travelers will visit countries where bacteria that cause travelers' diarrhea are endemic, particularly Africa, Asia and Latin America, and about 20 million of those travelers will develop travelers' diarrhea.

Travelers' diarrhea (TD) is caused by ingestion of pathogens in contaminated food and water. Of the 54 million travelers to endemic areas, an estimated 17 million will contract TD, making it one of the most common illnesses in travelers. Symptoms last for 3 to 5 days, and 55 percent of subjects who become ill have more than six stools daily, with an average of 18 total stools per episode. TD is often accompanied by nausea, vomiting and cramping and can result in severe dehydration, mimicking the symptoms of cholera. Although generally self-limited, TD is often accompanied by prostration and can require hospitalization, often in
'/>"/>

SOURCE Iomai Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Iomai to Announce Results From Phase 1 Influenza Trial and Host Webcast Tomorrow
2. Iomai Dose-Ranging Trial Demonstrates Needle-Free Patch Vaccine for Travelers Diarrhea Stimulates Immune Response Even at Low Doses
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014   Bluegrass Vascular Technologies ... innovating lifesaving devices and methods for vascular access, ... Series A financing, which was led by ... deal will allow Bluegrass Vascular to obtain CE ... enhance manufacturing capabilities, and proceed with US regulatory ...
(Date:7/30/2014)... Nev. , July 30, 2014  PDL BioPharma, ... that company management will participate in the Jefferies 2014 ... , Massachusetts. The conference will occur on August 6, ... PDL BioPharma, Inc. PDL BioPharma manages a ... its Queen et al. antibody humanization patents and license ...
(Date:7/30/2014)... 30. Juli 2014 Die Apex ... Anbieter im Bereich Atemtherapie- und Druckzonenprodukte, gibt ... München in Deutschland anfechten werden. Dieses hat ... ein Patent von ResMed verletze. Apex weist ... Ländern gegen verschiedene Patente von ResMed Anfechtungen ...
Breaking Medicine Technology:Bluegrass Vascular Technologies Raises $4.5M Series A Financing Led By Targeted Technology Funds 2PDL BioPharma to Participate in Jefferies 2014 Boston Healthcare Summit 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 3
... and Potentially Suited for Once,Daily Administration, PRINCETON, ... an innovator in the discovery and development ... results,from the initial Phase 1 clinical trial ... for the treatment of hypertension,and diabetic nephropathy. ...
... for potential combination,therapies and details of N3/4A ... April 11, 2007 /PRNewswire-FirstCall/ --,InterMune, Inc. announced ... vitro experiments concerning its HCV protease inhibitor,ITMN-191, ... at the 42nd,Annual Meeting of the European ...
Cached Medicine Technology:Pharmacopeia Announces Positive Results from Initial DARA Clinical,Trial 2Pharmacopeia Announces Positive Results from Initial DARA Clinical,Trial 3Pharmacopeia Announces Positive Results from Initial DARA Clinical,Trial 4Pharmacopeia Announces Positive Results from Initial DARA Clinical,Trial 5InterMune Presents Research on ITMN-191 in Hepatitis C at EASL,Annual Meeting 2InterMune Presents Research on ITMN-191 in Hepatitis C at EASL,Annual Meeting 3InterMune Presents Research on ITMN-191 in Hepatitis C at EASL,Annual Meeting 4
(Date:7/30/2014)... July 30, 2014 The Technology Association ... Alliance of TAG (B&TA), today issued its final call ... Awards. , Interested companies have until August 29th 2014 ... Semi-Finalists will be selected by the Excalibur Judging Committee. ... meet with the judges for interviewing process. , ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 As the ... ) in gynecological surgeries continues to grow, Bernstein Liebhard ... to those calling for a ban on uterine morcellation. ... Valverde was diagnosed with leiomyosarcoma following a hysterectomy that ... year of her diagnosis, the aggressive cancer had progressed ...
(Date:7/30/2014)... New York, NY (PRWEB) July 30, 2014 ... largest nutrition school, is pleased to announce that Arianna Huffington ... in the curriculum of the Health Coach Training Program ... of The Huffington Post, a world-renowned news and blogging site ... Huffington is the author of fourteen books and was included ...
(Date:7/30/2014)... The report "Peracetic Acid Market by Type (Disinfectant, Sanitizer, ... Pulp & Paper, & Others), by Geography (North America, ... to 2018". Peracetic Acid Market is projected to reach ... a robust growth rate of over 6.2% during the ... and 33 figures spread through 221 Slides and in-depth ...
(Date:7/30/2014)... sub-groups of cells jockeying for supremacy within a cancerous ... can proliferate the fastest, researchers at Dana-Farber Cancer Institute ... publication of the journal Nature . The ... with precision medicines, the study authors explained: Doctors need ... tumor,s growth and metastasis and select drugs that target ...
Breaking Medicine News(10 mins):Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 2Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 3Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 2Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 3Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 4Health News:Arianna Huffington Joins Integrative Nutrition as a Guest Speaker 2Health News:Arianna Huffington Joins Integrative Nutrition as a Guest Speaker 3Health News:Peracetic Acid Market Worth $664.24 Million by 2018 – New Report by MarketsandMarkets 2Health News:Peracetic Acid Market Worth $664.24 Million by 2018 – New Report by MarketsandMarkets 3Health News:Peracetic Acid Market Worth $664.24 Million by 2018 – New Report by MarketsandMarkets 4Health News:Target growth-driving cells within tumors, not fastest-proliferating cells 2Health News:Target growth-driving cells within tumors, not fastest-proliferating cells 3
... , ... VP for Healthcare Industry , ... Dayton, OH (Vocus) September 28, 2009 -- Sogeti, a leading international provider of professional IT ... Healthcare to further the industry expertise that it provides to clients., , ,With ...
... them, survey shows , MONDAY, Sept. 28 (HealthDay News) -- ... the growth charts widely used in pediatrician,s offices, but many ... a new survey shows. , About 85 percent of parents ... and correctly identify that the point corresponded to the child,s ...
... Life Care Centers ... 21., at its headquarters in Cleveland, Tenn. , ... Cleveland, Tenn. (Vocus) September 28, 2009 -- Life Care Centers of America ... its headquarters in Cleveland, Tenn., , ,The Chairman,s Award for outstanding commitment to excellence went ...
... ... a medical conference offered by the American Academy of Environmental Medicine in Phoenix, Arizona, October ... ... allergies have risen 24% among children under 5 years of age and 19% among children ...
... the number of women opting for surgery to remove the healthy ... a lack of evidence that the surgery can improve survival. The ... choose to have both breasts removed because of a strong family ... and has changed little in the last decade. The study appears ...
... Take precautions to avoid falls, strains and sprains, experts ... health and safety precautions when raking leaves, cleaning gutters ... according to the American Academy of Orthopaedic Surgeons (AAOS). ... the autumn season, and it often takes a toll ...
Cached Medicine News:Health News:Sogeti USA Grows to Ensure Industry Expertise for Clients 2Health News:Sogeti USA Grows to Ensure Industry Expertise for Clients 3Health News:Children's Growth Charts Don't Measure Up With Parents 2Health News:Children's Growth Charts Don't Measure Up With Parents 3Health News:Life Care Centers of America Awards Excellence 2Health News:Life Care Centers of America Awards Excellence 3Health News:Body Under Siege: Inflammation and Autoimmunity Conference Offered to Physicians 2Health News:Body Under Siege: Inflammation and Autoimmunity Conference Offered to Physicians 3Health News:Body Under Siege: Inflammation and Autoimmunity Conference Offered to Physicians 4Health News:More women choosing to remove healthy breast after cancer diagnosis 2Health News:Autumn Chores Often Hazardous 2
... LMA ™ Airway., ,The LMA ... which allows it to be positioned ... maintaining a good seal. This makes ... dental surgery, or other procedures where ...
... The Intubating LMA™ Airway. , ... or unexpected difficult airway, the LMA Fastrach™ ... without moving the head or neck. The ... attempts. , ,Selected by emergency teams ...
... Most Versatile LMA™ Airway., ,The LMA ... The double cuff design enables seal pressures ... achieved. The drain tube separates the alimentary ... the flexible airway tube, enable longer periods ...
... As experts in the ... Portex can offer an integrated ... management requirements. The single-use Portex ... an important addition to this ...
Medicine Products: